粪菌移植治疗肥胖及代谢相关脂肪性肝病的临床研究进展

Research progress on fecal microbiota transplantation in the treatment of obesity and metabolic dysfunction-associated steatotic liver disease

肠道微生态紊乱深度参与肥胖及代谢相关脂肪性肝病的发生发展。粪菌移植作为一种新型肠道菌群调节及治疗手段,其在肥胖及代谢相关脂肪性肝病治疗中的应用备受关注,近年国内外相继开展大量临床研究进行积极深入探索。粪菌移植在肥胖治疗中对体重的直接疗效十分有限,对相关代谢紊乱的缓解作用仍不明确,但其在辅助减重术后体重管理具有前景,对于肥胖及代谢相关脂肪性肝病瘦人亚型脂肪含量改善可能有积极帮助。本文就粪菌移植在肥胖及代谢相关脂肪性肝病的治疗临床证据进行总结及阐述。

Gut microbiota dysbiosis plays a significant role in the development of metabolic dysfunction-associated steatotic liver disease(MASLD).Fecal microbiota transplantation(FMT),as a novel approach for gut microbiota modulation and therapy,has garnered considerable attention in the treatment of obesity and MASLD.Numerous clinical studies have been conducted in recent years both domestically and internationally,actively exploring its applications.FMT has shown limited direct efficacy in weight reduction for treating obesity and its effects on alleviating associated metabolic disorders remain unclear.However,it holds promise in weight management following bariatric surgery and may offer positive outcomes in improving hepatic steatosis among lean obese individuals and with MASLD subtypes.This paper summarizes and discusses the clinical evidence of FMT in the treatment of obesity and MASLD.